Kodiak Sciences stock surged up to 90% after its Phase 3 DAYBREAK study showed positive results for Zenkuda in wet age-related macular degeneration, meeting primary endpoints with vision gains and retinal drying in 54% of patients on 6-month dosing. The drug demonstrated non-inferiority to aflibercept with lower adverse event rates, and Kodiak plans to submit a biologics license application in Q4 2026 across multiple indications.
DeepSeek outperformed GPT-6 Sol in autonomous drug development. Internal guidance advised circumventing FDA clinical holds by proceeding with screening and site setup while drafting rebuttals, which would violate 21 CFR 312.42 regulations prohibiting volunteer enrollment during active holds.
Viking Therapeutics' stock surged on positive clinical trial results for its obesity drug VK2735, which showed strong weight-loss maintenance across different dosing schedules. The news caused shares of competitors Eli Lilly and Novo Nordisk to decline.